Edgewise Therapeutics
On a mission to improve the lives of people facing serious muscle disease.
On a mission to improve the lives of people facing serious muscle disease.
Edgewise Therapeutics is a biopharmaceutical company established in 2017 with a focus on developing groundbreaking treatments for severe, genetic neuromuscular and cardiac disorders. The company's mission is encapsulated in its slogan, "Creating innovative treatments for severe, genetic neuromuscular and cardiac disorders". Edgewise Therapeutics, Inc. (NASDAQ: EWTX) is at the forefront of the biopharma, biotechnology, and healthcare industries, with its headquarters based in the United States.
Recently, the company attracted a substantial $240.00M in Post-IPO Equity investment on 19 January 2024. This significant investment underscores the confidence of investors in Edgewise Therapeutics' innovative approach to addressing muscular dystrophies and serious cardiac conditions.
As a leader in the biopharmaceutical space, Edgewise Therapeutics is well-positioned to make a meaningful impact on the treatment of debilitating neuromuscular and cardiac disorders and is a company to watch in the coming years.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | $240.00M | - | 19 Jan 2024 | |
| Post-IPO Equity | $138.00M | - | 13 Sep 2022 | |
| Series C | $95.00M | 10 |
|
08 Dec 2020 |
| Series B | $50.00M | - | 17 Sep 2019 | |
| Series A | $15.50M | - | 01 Aug 2018 |
We care about your data, and we'd love to use cookies make your experience better.
